What is amoxapine brand name?

Amoxapine (Brand Names: Asendin) is a tricyclic antidepressant used to treat symptoms of depression, anxiety, or agitation.

What does amoxapine do to the body?

Amoxapine is used to treat depression. Amoxapine is in a class of medications called tricyclic antidepressants (TCAs). It works by increasing the amounts of certain natural substances in the brain that are needed to maintain mental balance.

Is amoxapine available in the US?

Amoxapine, sold under the brand name Asendin among others, is a tricyclic antidepressant (TCAs). It is the N-demethylated metabolite of loxapine. Amoxapine first received marketing approval in the United States in 1992 (approximately 30 to 40 years after most of the other TCAs were introduced in the United States).

How long does amoxapine take to work?

It’s a tricyclic antidepressant. How long does it take amoxapine to work? Most people will start to feel the effects of amoxapine within two weeks, but some people might feel the effects between four and seven days after starting.

Does amoxapine cause weight gain?

Tricyclic antidepressants Tricyclic antidepressants, also known as cyclic antidepressants or TCAs, may cause weight gain. These drugs include: amitriptyline (Elavil) amoxapine.

Can you just stop taking amoxapine?

Keep using the medication as directed and tell your doctor if your symptoms do not improve. Do not stop using amoxapine suddenly, or you could have unpleasant withdrawal symptoms.

Does Amoxapine cause weight gain?

Is amoxapine an antipsychotic?

Amoxapine is marketed as an antidepressant. However, its invitro profile, receptor occupancy and preclinical effects are very similar to atypical antipsychotics. Amoxapine has also shown efficacy as an atypical antipsychotic in open trials.

Is amoxapine an antipsychotic drug?

Amoxapine is marketed as an antidepressant. However, its in-vitro profile, receptor occupancy and preclinical effects are very similar to atypical antipsychotics. Amoxapine has also shown efficacy as an atypical antipsychotic in open trials.